Sona Nanotech Inc C.SONA

Alternate Symbol(s): SNANF

Technology Scientific & Technical Instruments

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.

CSE:SONA - Post by User

Sona Nanotech Inc > You clowns had better read this

<< Previous

Bullboard Posts

Next >>

Comment by shoosh22on Aug 29, 2020 1:18pm

148 Views

Post# 31475300

RE:RE:RE:RE:RE:RE:RE:RE:You clowns had better read this

I don't know if Irroc CSE has a rule against that but if not there should be a way of summing up quickly the important bits.. Bolding them help significantly imo. The bit about the CDC should have been a new paragraph as it sounds confusing reading that right after the bit on Saudi study.

The voice of the investors can move the company to make changes. Everyone take 5 and email the company. david@sonanano.com. It is David's responsibility as CEO. Definitely need some improvement in PR. I could have written that NR better.. explained what the numbers meant for one, & clinical lab results vs Field studies. Some real background on the Saudi Lab, and importance of this study. Keep Sona a class act. When they move to the Nasdaq I'm sure they will upgrade their PR company.

I highlighted one sentence below. There must be at least 5 topics covered. Does anyone really know what it means after one reading. If you knew nothing about Sona you would have no idea.

Findingmoney wrote:
What if they made bold some points that do not jump out, it may help but it could have been presented as a little more unique in the detection capabilities displayed comparatively with other tests in general. IMO

Here it is with a little bold thrown in:

Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its rapid detection COVID-19 antigen test achieved a sensitivity of 84.6% and a specificity of 90.0% in a study across 99 collected clinical patient samples, which included 39 positive samples and 60 negative samples, as determined by RT-PCR testing. The Company is now continuing its submission of data to both the FDA and Health Canada to support their requirements for emergency use authorization approvals.

Darren Rowles, President and Chief Scientific Officer of Sona Nanotech comments, "Rapid, point-of-care, antigen tests can make a significant contribution to reducing the spread of COVID-19 by detecting the presence of the virus, potentially before the onset of symptoms. This achievement is the result of the extraordinary work and dedication by the entire Sona team and our partners."

The Company partnered with the King Fahd Research Center lab at King Abdulaziz University within SaudiVax, a life sciences joint venture between PnuVax Inc. of the United States and UYC Inc. of Saudi Arabia, to deliver the results of the study, which is complemented by previously released in-laboratory, analytical results from both the Company and MRIGlobal in Kansas City. Those latter evaluations determined test sensitivity of 96%, test specificity of 96% and a Limit of Detection ("LOD") of 2.1 x 10² TCID^50.Clinical testing protocols are paramount as the CDC advises that proper collection of specimens is the most important step in the laboratory diagnosis of infectious diseases, whether the collection be for RT-PCR or rapid antigen tests, as swab application technique can strongly influence results.

Dr. Anwar Hashem, SaudiVax Chief Scientific Officer and the Deputy Director of King Fahd Medical Research Center at King Abdulaziz University commented, "As a leading medical research center, we have conducted clinical evaluation studies on several point-of-care antigen tests and found Sona Nanotech's rapid antigen test to perform by far the best, and we believe it could be a valuable addition to the existing diagnostic solutions needed to combat this pandemic."

The Company's rapid, antigen COVID-19 test utilizes a nasopharyngeal swab and provides a result in 15 minutes without the use of either laboratory equipment or a reader.

The Company cautions that its COVID-19 rapid antigen test is not yet approved by the FDA or other regulatory bodies and will update the market as appropriate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 virus (or SARS-2 Coronavirus) at this time.